Floatz logo

Sonovue

Von-Hippel Lindau

UNC Lineberger Comprehensive Cancer CenterPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Von-Hippel Lindau cohort.

Asset / SponsorPhaseRating
Belzutifan
Merck Sharp & Dohme LLC
Phase 3BB
Palbociclib
Merck Sharp & Dohme LLC
Phase 3B
LENVATINIB
Merck Sharp & Dohme LLC
Phase 3B
Nivolumab
Merck Sharp & Dohme LLC
Phase 3B
Everolimus
Merck Sharp & Dohme LLC
Phase 3B

View all 16 →

Same molecule, other indications

Sonovue is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
carotid stenosisDormant
B
Indicative ·
62 / 100
View asset →
stroke disorderDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →